Related Experiment Video
Updated: May 25, 2026
Human Blastocyst Biopsy and Vitrification
Published on: July 26, 2019
A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with
Paul Devroey1, Antonio Pellicer, Anders Nyboe Andersen
1Center for Reproductive Medicine, University Hospital Brussels, Brussels, Belgium.
Objective:
To compare the efficacy and safety of highly purified menotropin (hphMG) and recombinant FSH (rFSH) for controlled ovarian stimulation in a GnRH antagonist cycle with compulsory single-blastocyst transfer.
Design:
Randomized, open-label, assessor-blind, parallel groups, multicenter, noninferiority trial.
Setting:
Twenty-five infertility centers in seven countries.
Patient(S):
Seven hundred forty-nine women.
Intervention(S):
Controlled ovarian stimulation with hphMG or rFSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer on day 5 in one fresh or subsequent frozen blastocyst replacement in natural cycles initiated within 1 year of each patient's start of treatment.
Main Outcome Measure(S):
Ongoing pregnancy (primary end point) and live birth rates, as well as pharmacodynamic parameters.
Result(S):
The ongoing pregnancy rate after a fresh cycle was 30% with hphMG versus 27% with rFSH for the per-protocol (PP) population and 29% versus 27% for the intention-to-treat (ITT) population. Noninferiority of hphMG compared to rFSH was established. Considering frozen cycles initiated within 1 year, the cumulative live birth rate for a single stimulation cycle was 40% and 38% for women treated with hphMG and rFSH, respectively (both PP and ITT). Significant differences in pharmacodynamic end points were found between the two gonadotropin preparations.
Conclusion(S):
Highly purified hMG is at least as effective as rFSH in GnRH antagonist cycles with compulsory single-blastocyst transfer.
Clinical Trial Registration Number:
NCT00884221.
